Kymera Therapeutics Inc - Asset Resilience Ratio
Kymera Therapeutics Inc (KYMR) has an Asset Resilience Ratio of 30.37% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Kymera Therapeutics Inc's Asset Resilience Ratio has changed over time. Check Kymera Therapeutics Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Kymera Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Kymera Therapeutics Inc (KYMR) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $506.84 Million | 30.37% |
| Total Liquid Assets | $506.84 Million | 30.37% |
Asset Resilience Insights
- Very High Liquidity: Kymera Therapeutics Inc maintains exceptional liquid asset reserves at 30.37% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Kymera Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Kymera Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for Kymera Therapeutics Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Kymera Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 28.19% | $491.26 Million | $1.74 Billion | -9.49pp |
| 2024-12-31 | 37.68% | $368.49 Million | $978.03 Million | -8.34pp |
| 2023-12-31 | 46.01% | $264.92 Million | $575.76 Million | -10.16pp |
| 2022-12-31 | 56.17% | $338.77 Million | $603.13 Million | -8.93pp |
| 2021-12-31 | 65.10% | $394.44 Million | $605.90 Million | +10.66pp |
| 2020-12-31 | 54.44% | $265.20 Million | $487.18 Million | +40.78pp |
| 2019-12-31 | 13.66% | $15.94 Million | $116.70 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $44.23 Million | -- |
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CR… Read more